全文获取类型
收费全文 | 15398篇 |
免费 | 1165篇 |
国内免费 | 490篇 |
专业分类
耳鼻咽喉 | 182篇 |
儿科学 | 460篇 |
妇产科学 | 226篇 |
基础医学 | 1760篇 |
口腔科学 | 303篇 |
临床医学 | 1665篇 |
内科学 | 3078篇 |
皮肤病学 | 279篇 |
神经病学 | 972篇 |
特种医学 | 494篇 |
外国民族医学 | 4篇 |
外科学 | 1593篇 |
综合类 | 1485篇 |
一般理论 | 2篇 |
预防医学 | 1172篇 |
眼科学 | 505篇 |
药学 | 1264篇 |
9篇 | |
中国医学 | 506篇 |
肿瘤学 | 1094篇 |
出版年
2024年 | 26篇 |
2023年 | 166篇 |
2022年 | 241篇 |
2021年 | 590篇 |
2020年 | 422篇 |
2019年 | 431篇 |
2018年 | 596篇 |
2017年 | 453篇 |
2016年 | 414篇 |
2015年 | 576篇 |
2014年 | 686篇 |
2013年 | 769篇 |
2012年 | 1125篇 |
2011年 | 1188篇 |
2010年 | 751篇 |
2009年 | 520篇 |
2008年 | 813篇 |
2007年 | 847篇 |
2006年 | 724篇 |
2005年 | 791篇 |
2004年 | 671篇 |
2003年 | 631篇 |
2002年 | 598篇 |
2001年 | 483篇 |
2000年 | 527篇 |
1999年 | 424篇 |
1998年 | 131篇 |
1997年 | 112篇 |
1996年 | 116篇 |
1995年 | 105篇 |
1994年 | 62篇 |
1993年 | 54篇 |
1992年 | 148篇 |
1991年 | 121篇 |
1990年 | 104篇 |
1989年 | 111篇 |
1988年 | 90篇 |
1987年 | 76篇 |
1986年 | 68篇 |
1985年 | 50篇 |
1984年 | 38篇 |
1983年 | 25篇 |
1982年 | 13篇 |
1981年 | 9篇 |
1980年 | 11篇 |
1979年 | 14篇 |
1977年 | 12篇 |
1973年 | 9篇 |
1970年 | 9篇 |
1965年 | 8篇 |
排序方式: 共有10000条查询结果,搜索用时 296 毫秒
1.
2.
3.
4.
5.
Maria Gonzalez-Cao Cristina Carrera Juan Francisco Rodriguez Moreno Pedro Rodríguez-Jiménez Mónica Antoñanzas Basa Rosa Feltes Ochoa Teresa Puertolas Eva Muñoz-Couselo José Luis Manzano Ivan Marquez-Rodas Juan Martín-Liberal Ainara Soria Pilar Lopez Criado Almudena Garcia-Castaño Aram Boada Pablo Ayala de Miguel Susana Puig Guillermo Crespo Alfonso Berrocal 《Journal of the American Academy of Dermatology》2021,84(5):1412-1415
6.
7.
Treatment of posterior eye diseases is more challenging than the anterior segment ailments due to a series of anatomical barriers and physiological constraints confronted by drug delivery to the back of the eye. In recent years, concerted efforts in drug delivery have been made to prolong the residence time of drugs injected in the vitreous humor of the eye. Our previous studies demonstrated that poly(ortho ester) (POE) nanoparticles were biodegradable/biocompatible and were capable of long-term sustained release. The objective of the present study was to investigate the safety and localization of POE nanoparticles in New Zealand white rabbits and C57BL/6 mice after intravitreal administration for the treatment of chronic posterior ocular diseases. Two concentration levels of POE nanoparticles solution were chosen for intravitreal injection: 1.5?mg/ml and 10?mg/ml. Our results demonstrate that POE nanoparticles were distributed throughout the vitreous cavity by optical coherence tomography (OCT) examination 14 days post-intravitreal injection. Intraocular pressure was not changed from baseline. Inflammatory or adverse effects were undetectable by slit lamp biomicroscopy. Furthermore, we demonstrate that POE nanoparticles have negligible toxicity assessed at the cellular level evidenced by a lack of glia activation or apoptosis estimation after intravitreal injection. Collectively, POE nanoparticles are a novel and nontoxic as an ocular drug delivery system for the treatment of posterior ocular diseases. 相似文献
8.
Ana M. Gómez Angelica Imitola Diana Henao Maira García-Jaramillo Marga Giménez Clara Viñals Bruno Grassi Mariana Torres Isabella Zuluaga Oscar Mauricio Muñoz Martin Rondón Fabián León-Vargas Ignacio Conget 《Diabetes & Metabolic Syndrome: Clinical Research & Reviews》2021,15(1):267-272
Background and aimsDespite using sensor-augmented pump therapy (SAPT) with predictive low-glucose management (PLGM), hypoglycemia is still an issue in patients with type 1 Diabetes (T1D). Our aim was to determine factors associated with clinically significant hypoglycemia (<54 mg/dl) in persons with T1D treated with PLGM-SAPT.Methodology: This is a multicentric prospective real-life study performed in Colombia, Chile and Spain. Patients with T1D treated with PLGM-SAPT, using sensor ≥70% of time, were included. Data regarding pump and sensor use patterns and carbohydrate intake from 28 consecutive days were collected. A bivariate and multivariate Poisson regression analysis was carried out, to evaluate the association between the number of events of <54 mg/dl with the clinical variables and patterns of sensor and pump use.Results188 subjects were included (41 ± 13.8 years-old, 23 ± 12 years disease duration, A1c 7.2% ± 0.9). The median of events <54 mg/dl was four events/patient/month (IQR 1–10), 77% of these events occurred during day time. Multivariate analysis showed that the number of events of hypoglycemia were higher in patients with previous severe hypoglycemia (IRR1.38; 95% CI 1.19–1.61; p < 0.001), high glycemic variability defined as Coefficient of Variation (CV%) > 36% (IRR 2.09; 95%CI 1.79–2.45; p < 0.001) and hypoglycemia unawareness. A protector effect was identified for adequate sensor calibration (IRR 0.77; 95%CI 0.66–0.90; p:0.001), and the use of bolus wizard >60% (IRR 0.74; 95%CI 0.58–0.95; p:0.017).ConclusionIn spite of using advanced SAPT, clinically significant hypoglycemia is still a non-negligible risk. Only the identification and intervention of modifiable factors could help to prevent and reduce hypoglycemia in clinical practice. 相似文献
9.
José A. Lorente Pablo Cardinal-Fernández Diego Muñoz Fernando Frutos-Vivar Arnaud W. Thille Carlos Jaramillo Aida Ballén-Barragán José M. Rodríguez Oscar Peñuelas Guillermo Ortiz José Blanco Bruno Valle Pinheiro Nicolás Nin María del Carmen Marin Andrés Esteban Taylor B. Thompson 《Intensive care medicine》2015,41(11):1921-1930
10.